{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:41:26Z","timestamp":1770975686294,"version":"3.50.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/ico.0b013e318160d019","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:54:47Z","timestamp":1236272087000},"page":"357-362","source":"Crossref","is-referenced-by-count":36,"title":["Effect of Subconjunctival Bevacizumab (Avastin) on Experimental Corneal Neovascularization in Guinea Pigs"],"prefix":"10.1097","volume":"27","author":[{"given":"Volkan","family":"Hurmeric","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarkan","family":"Mumcuoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuneyt","family":"Erdurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan","family":"Dagli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H","family":"Durukan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy.","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"R2-21-20210204","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea.","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"key":"R3-21-20210204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1167\/iovs.01-1277","article-title":"VEGF-dependent conjunctivalization of the corneal surface.","volume":"44","author":"Joussen","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-21-20210204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine.","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R5-21-20210204","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00417-007-0542-4","article-title":"Inhibition of corneal angiogenesis by ascorbic acid in the rat model.","volume":"245","author":"Peyman","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-21-20210204","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00417-002-0591-7","article-title":"Inhibition of experimental angiogenesis of cornea by somatostatin.","volume":"241","author":"Wu","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-21-20210204","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0161-6420(86)33581-4","article-title":"Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty.","volume":"93","author":"Nirankari","year":"1986","journal-title":"Ophthalmology"},{"key":"R8-21-20210204","first-page":"2148","article-title":"Fine needle diathermy occlusion of corneal vessels.","volume":"41","author":"Pillai","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-21-20210204","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/exer.1998.0527","article-title":"Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization.","volume":"67","author":"Gohto","year":"1998","journal-title":"Exp Eye Res"},{"key":"R10-21-20210204","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00003226-200307000-00018","article-title":"Photodynamic therapy of corneal neovascularization with verteporfin.","volume":"22","author":"Fossarello","year":"2003","journal-title":"Cornea"},{"key":"R11-21-20210204","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00003226-200009000-00014","article-title":"Changing concepts in the management of severe ocular surface disease over twenty-five years.","volume":"19","author":"Holland","year":"2000","journal-title":"Cornea"},{"key":"R12-21-20210204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.preteyeres.2006.09.001","article-title":"Regulation of corneal angiogenesis in limbal stem cell deficiency.","volume":"25","author":"Ma","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"R13-21-20210204","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol Cancer Res"},{"key":"R14-21-20210204","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"key":"R15-21-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0002-9440(10)65539-3","article-title":"What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?","volume":"153","author":"Nicosia","year":"1998","journal-title":"Am J Pathol"},{"key":"R16-21-20210204","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1247\/csf.26.25","article-title":"Structure and function of VEGF\/VEGF-receptor system involved in angiogenesis.","volume":"26","author":"Shibuya","year":"2001","journal-title":"Cell Struct Funct"},{"key":"R17-21-20210204","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.","volume":"13","author":"Ranieri","year":"2006","journal-title":"Curr Med Chem"},{"key":"R18-21-20210204","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R19-21-20210204","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","article-title":"Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.","volume":"19","author":"Binetruy-Tournaire","year":"2000","journal-title":"EMBO J"},{"key":"R20-21-20210204","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R21-21-20210204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization.","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"R22-21-20210204","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases.","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R23-21-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"R24-21-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R25-21-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R26-21-20210204","first-page":"216","article-title":"Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas.","volume":"25","author":"Onguru","year":"2006","journal-title":"Clin Neuropathol"},{"key":"R27-21-20210204","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"R28-21-20210204","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am J Pathol"},{"key":"R29-21-20210204","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.","volume":"288","author":"Lin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R30-21-20210204","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"key":"R31-21-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularization by bevacizumab (AVASTIN).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R32-21-20210204","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","article-title":"Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.","volume":"22","year":"2002","journal-title":"Retina"},{"key":"R33-21-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R34-21-20210204","first-page":"1112","article-title":"Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea.","volume":"40","author":"Edelman","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"R35-21-20210204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.9-suppl_1-36","article-title":"Maximizing the potential of bevacizumab in cancer treatment.","volume":"9","author":"Bergsland","year":"2004","journal-title":"Oncologist"},{"key":"R36-21-20210204","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer.","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"R37-21-20210204","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"R38-21-20210204","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1167\/iovs.06-0433","article-title":"Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.","volume":"47","author":"Costa","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R39-21-20210204","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R40-21-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R41-21-20210204","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"R42-21-20210204","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-200804000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:30:25Z","timestamp":1738978225000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200804000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318160d019","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}